Skip to content

Candel Therapeutics, Inc. CADL Free cash flow margin

Discontinued — last reported Q4 '22

Free cash flow margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
24.6%-2.9pp
Amgen logo
AmgenAMGN
23.1%-8.9pp
Gilead Sciences logo
Gilead SciencesGILD
34.4%+0.1pp
CG Oncology logo
CG OncologyCGON
-3,163.8%-1,351pp
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-225.6%-334pp
Regenxbio logo
RegenxbioRGNX
-269.2%-364pp

Other financials

Income statement

See full
Revenue$31.0K0.0%
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation

See full
Market cap$693.87M+192%
Enterprise value$501.88M+220%
P/S5,595.7×-18,674×

Profitability

See full
Operating margin-28,000.8%+15,050pp
Net margin-15,156.5%-5,064pp

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity-0.1×
Current ratio28×+23.4×

Where this comes from

Calculated from Candel Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Candel Therapeutics, Inc.’s 10-K, filed March 28, 2024, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s free cash flow margin?
Candel Therapeutics, Inc. (CADL) reported free cash flow margin of -26,383.9% in Q4 2022.
How has Candel Therapeutics, Inc.'s free cash flow margin changed year-over-year?
Candel Therapeutics, Inc.'s free cash flow margin decreased by 36.0% year-over-year, from -19,397.6% to -26,383.9%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.